IRON IS ABSOLUTELY MELTING FACES: APOLLO TRIAL SMASHED AND THE FDA IS NEXT
$IRON IS EATING THE SHORT SELLERS FOR BREAKFAST πππ
Listen up you absolute degens. If you missed the jump in $IRON, go back to trading penny stocks on your momβs Robinhood account. We are seeing a 38.31% rip to the upside, currently hanging out near $78. This isn't retail FOMO; this is institutional capital finally waking up to the reality of the biotech cycle.
| Metric | Value |
|---|---|
| Current Price | $78.00 |
| Move % | +38.31% |
| Trend Trigger | $70.24 (Flipped) |
| Bull vs Bear Score | 18.5 vs 32.6 (Lagging) |
THE CATALYST: APOLLO TRIAL DATA IS PURE ALPHA
The Phase 3 APOLLO trial for bitopertin in EPP didn't just pass; it crushed every single endpoint. Co-primaries? Nailed. Secondaries? Nailed. After that trash Complete Response Letter back in February, the shorts got arrogant. They thought $IRON was dead in the water. They were wrong. Management is planning to refile with the FDA before 2026 hits the history books. Thatβs not 'news'; thatβs a massive catalyst for an institutional re-rating.
SO WHAT?
Biotech is binary. Either you hold the bag or you catch the rocket. $IRON just signaled itβs a rocket. The bears are still clinging to their 32.6 score on the Bull vs Bear indicator, but that's just because they haven't updated their models for the reality of the APOLLO data yet. They are holding heavy bags of short interest that need to be covered. When they do? Weβre looking at a massive gamma squeeze to the triple digits.
THE PLAY
The Trend Engine flipped the script the second we smashed through the $70.24 level. If you aren't long yet, you're chasing, but the institutional momentum is real. Keep an eye on $ARQT and $BBC for similar biotech sympathy plays, but $IRON is the alpha leader today. Don't be the liquidity for the institutions. Hold the line, watch the $70.24 support level. If we close above, the shorts are getting liquidated.
Stay ruthless. ππππ
Data Source: VistaP Global Financial Analysis & Real-Time Exchange Feed (2026-10-19)
Disclaimer: Eachi Alpha provides independent financial analysis based on algorithmic market data. This content is for informational and educational purposes only and does not constitute financial, investment, or trading advice. Trading securities involves significant risk. Eachi Alpha is not responsible for any financial losses or damages resulting from the use of this information. Always perform your own due diligence before making investment decisions.